Hansa Biopharma
UnverifiedManufacturerLund, SwedenFounded 2007Nasdaq Stockholm: HNSA
Overview
Hansa Biopharma is a biopharmaceutical company founded in 2007 and based in Lund, Sweden, developing and commercializing immunomodulatory treatments for rare immunological conditions, built on its IgG-cleaving enzyme technology. In the US its lead product, imlifidase, has a BLA under FDA review for highly sensitized patients awaiting kidney transplantation (PDUFA action date December 19, 2026; marketed in Europe as IDEFIRIX). Hansa is listed on Nasdaq Stockholm and is building a US key-account team for the launch.
Hiring snapshot
Hiring by specialty
Open roles
Newest first, from Hansa Biopharma’s careers page.
- Key Account Manager - Atlanta, GAAtlanta, Georgia10d ago$170k–$205k
- Key Account Manager - Baltimore, MDBaltimore, Maryland10d ago$170k–$205k
- Key Account Manager - Boston, MABoston, Massachusetts10d ago$170k–$205k
- Key Account Manager - Chicago, ILChicago, Illinois10d ago$170k–$205k
- Key Account Manager - Cleveland, OHCleveland, Ohio10d ago$170k–$205k
- Key Account Manager - Dallas, TXDallas, Texas10d ago$170k–$205k
Divisions
Division information is pending company verification.Once Hansa Biopharma claims its page, you will see each division, who it calls on and how it pays.
Claim your pageMore from Hansa Biopharma
These sections fill in when Hansa Biopharma claims and verifies its page.